“With the initiation of THB335 clinical trials, we are advancing the development of our potentially best-in-class oral KIT inhibitor toward becoming an important treatment for patients living with chronic spontaneous urticaria and other mast-cell mediated inflammatory diseases,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. “We are continuing to conduct our development efforts with urgency given the significant unmet need in CSU and the potentially transformative benefit that TBH335 may deliver to patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD:
- Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
- Third Harmonic Bio (NASDAQ:THRD) Soars 109% YTD; Is It a Solid Bet for Growth Investors?
- Third Harmonic Bio Welcomes New Director, Geoff McDonough
- Third Harmonic Bio appoints McDonough to board of directors
- Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors